Analysts’ Recent Ratings Updates for DaVita (DVA)

by · The Markets Daily

A number of firms have modified their ratings and price targets on shares of DaVita (NYSE: DVA) recently:

  • 2/21/2026 – DaVita was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
  • 2/5/2026 – DaVita was given a new $158.00 price target on by analysts at Truist Financial Corporation.
  • 2/4/2026 – DaVita had its price target raised by analysts at UBS Group AG from $186.00 to $190.00. They now have a “buy” rating on the stock.
  • 2/4/2026 – DaVita was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
  • 2/3/2026 – DaVita had its “hold” rating reaffirmed by analysts at TD Cowen.
  • 2/3/2026 – DaVita had its price target raised by analysts at Barclays PLC from $143.00 to $158.00. They now have an “equal weight” rating on the stock.
  • 1/5/2026 – DaVita had its price target lowered by analysts at Truist Financial Corporation from $140.00 to $128.00. They now have a “hold” rating on the stock.
  • 12/29/2025 – DaVita had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

See Also